-
Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update
23 Apr 2024 17:54 GMT
… before the U.S. financial markets open.
David P. Luci … Ibezapolstat
Ibezapolstat is the Company's lead antibiotic … difficile but spares other Firmicutes and the important … required by law.
Investor Contact:
Acurx Pharmaceuticals, Inc.
David P …
-
5 Growth Stocks to Buy From the Best Money Managers
23 Apr 2024 18:08 GMT
… that markets to pharmaceutical and biotech companies with … -to-market motion and heavy investment in … industry through industry consolidation and capitalizing on the shortfalls of competitors. The company … growth stocks in Morningstar’s database.
Investors can …
-
Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024
23 Apr 2024 17:15 GMT
First quarter revenues of $2.37 billion, up 1.5% from 2023
First quarter reported diluted earnings per share ("EPS") of $1.72, down 3.4% from 2023; and adjusted diluted EPS of $2.04, flat with 2023
Full year 2024 revenues now expected to be …
-
Global Diabetes Drugs Market to Witness an Upsurge in Growth by 2030, Examines DelveInsight | Key Companies in the Market - Sanofi, AstraZeneca, Pfizer, Johnson & Johnson, Novartis, Merck & Co., Novo Nordisk, Eli Lilly and Company, Biocon
23 Apr 2024 17:00 GMT
New York, USA, April 23, 2024 (GLOBE NEWSWIRE) -- Global Diabetes Drugs Market to Witness an Upsurge in Growth by 2030, Examines DelveInsight | Key Companies in the Market - Sanofi, AstraZeneca, Pfizer, Johnson & Johnson, Novartis, Merck & Co., …
-
Expansion of Organic and Sustainable Agriculture Catapults the Pesticide Detection Market; FMI Analysts Predict Market Valuation to Surpass US$ 3,049.50 million by 2034
23 Apr 2024 15:30 GMT
… 18% of market shares in 2024.
The market size in … Established industry leaders face competition from rising firms and … the pharmaceuticals, biotechnology, retail, and chemical sectors, where she advises market … has an MBA in Finance from MIT School of …
-
Mammalian Cell Fermentation Technology Market anticipated journey towards the lucrative US$ 68 Billion valuation. At a CAGR of 10% by 2034 | Future Market Insights, Inc.
23 Apr 2024 16:30 GMT
NEWARK, Del, April 23, 2024 (GLOBE NEWSWIRE) -- The mammalian cell fermentation technology market is estimated to be worth US$ 45.9 billion in 2024 and is projected to be valued at US$ 68 billion by 2034. Between 2024 and 2034, the industry is expected to …
-
US open: Stocks higher as investors digest Q1 earnings
23 Apr 2024 17:00 GMT
As of 1530 BST, the Dow Jones Industrial Average was up 0.36% at 38,376.02, while the S&P 500 advanced 0.83% to 5,052.34, while the Nasdaq Composite came out the gate 1.15% firmer at 15,629.29.
The Dow opened 136.04 points higher on Tuesday, extending …
-
Company presentations at BIO 2024 inspire partnering
23 Apr 2024 15:32 GMT
Company presentations at the BIO International Convention put innovators on stage before a small but important audience, helping them engage in the networking and partnering that are a hallmark of the event.
Partnering drives the biotech industry, and the …
-
Brise raises $20M; Taro shareholder criticizes Sun Pharma deal
23 Apr 2024 16:05 GMT
… among other investors. The Shanghai-based company is developing … Krensavage Asset Management — Taro Pharmaceutical Industries’ largest minority shareholder — … based “on an investment bank’s flawed … in cash for shares that it doesn …
-
Semler Scientific to Report First Quarter Financial Results and Host Conference Call on May 7, 2024
23 Apr 2024 17:15 GMT
SANTA CLARA, Calif., April 23, 2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today …